Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
Servier
Servier
EMD Serono
Grey Wolf Therapeutics
Palleon Pharmaceuticals, Inc.
Sensei Biotherapeutics, Inc.
Icahn School of Medicine at Mount Sinai
OncoResponse, Inc.
Vanderbilt-Ingram Cancer Center
OncoResponse, Inc.
Sanofi